As PCSCs express high levels of CCR5 (CCL5 receptor) than non-stem prostate cancer cells, developing PSCSs-targeting drug delivery system loaded with CCR5-specific small molecular inhibitors (i.g. maraviroc) to block the CCL5-CCR5 axis in PCSCs may represent a potential treatment strategy to eliminate PCSCs. This evidence concerns the gene CCL5 and prostate carcinoma.